omniture

TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting

TaiGen Biotechnology Co., Ltd.
2009-12-07 17:41 1297

TAIPEI, Taiwan, Dec. 7 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

The clinical data of Phase 1 study will be presented. In this randomized, double-blind, placebo-controlled, sequential ascending single intravenous dose study, TG-0054 exhibited excellent and favorable safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) profile. A maximally tolerated dose (MTD) was established. Good tolerability was observed. PK parameters showed dose proportionality over the dose range studied. PD results showed potent, dose-dependent mobilization of CD34+ hematopoietic stem cells and CD133+ endothelial progenitor cells into peripheral blood circulation.

The preclinical data will be reported on in vitro assays and in vivo studies in mouse models. TG-0054 demonstrated potent and selective antagonistic activities against CXCR4 in vitro. Significant mobilization of CD34+ hematopoietic stem cells and CD133+ endothelial progenitor cells was observed when TG-0054 was used alone or combined with G-CSF in preclinical models.

The preclinical and Phase I results support further clinical investigation. The Phase 2 study entitled "A Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease" will begin to enroll patients in December, 2009.

ASH 2009 Meeting Presentation:

Clinical

Oral presentation: TG-0054, a Novel and Potent Stem Cell Mobilizer,

Displays Excellent PK/PD and Safety Profile in Phase 1

Trial

Tuesday, December 8, 2009: 7:30 AM-9:00 AM

Preclinical

Poster: Rapid Mobilization of Murine Hematopoietic Stem and Progenitor

Cells with TG-0054, a Novel CXCR4 Antagonist (Poster Board

number: III-479)

Monday, December 7, 2009: 6:00 PM-8:00 PM

About TaiGen Biotechnology

TaiGen Biotechnology ( http://www.taigenbiotech.com/ ) is a leading development stage pharmaceutical company based in Taiwan with a wholly-owned subsidiary in Beijing, China. The company has a full capacity in discovery research and clinical development in China/Taiwan/US. Its current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market. In addition to TG-0054, Nemonoxacin, a novel broad-spectrum non-fluorinated quinolone with anti-MRSA activity and in- licensed from P&G Pharmaceuticals, achieved non-inferiority in clinical cure rate and safety profile compared with Levofloxacin in its Phase II CAP trial. The company has completed a second phase II study in diabetic foot infection to demonstrate Nemonoxacin's anti-MRSA activity with once-a-day oral dosing. TaiGen is seeking Nemonoxacin licensees for the US, EU and Japan markets. TaiGen also has HCV protease inhibitors in advanced preclinical programs to treat chronic hepatitis C infection.

TaiGen Contact

Dr. John Jin, VP Global Business Development

Tel: +886-2-2790-1861

Email: johnjin@taigenbiotech.com.tw

Source: TaiGen Biotechnology Co., Ltd.
collection